Wanting Song1, Yi Bai1, Jialin Zhu1, Fanxin Zeng1, Chunmeng Yang1, Beibei Hu1, Mingjun Sun1,2, Chenyan Li3, Shiqiao Peng3, Moye Chen4, Xuren Sun5. 1. Department of Gastroenterology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China. 2. Department of Gastrointestinal Endoscopy, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China. 3. Department of Endocrinology and Metabolism, First Hospital of China Medical University, Shenyang, Liaoning, China. 4. Department of Gastroenterology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China. rantong_722@163.com. 5. Department of Gastroenterology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China. sxr679@126.com.
Abstract
BACKGROUND: Gastric cancer (GC) represents a major malignancy and is the third deathliest cancer globally. Several lines of evidence indicate that the epithelial-mesenchymal transition (EMT) has a critical function in the development of gastric cancer. Although plentiful molecular biomarkers have been identified, a precise risk model is still necessary to help doctors determine patient prognosis in GC. METHODS: Gene expression data and clinical information for GC were acquired from The Cancer Genome Atlas (TCGA) database and 200 EMT-related genes (ERGs) from the Molecular Signatures Database (MSigDB). Then, ERGs correlated with patient prognosis in GC were assessed by univariable and multivariable Cox regression analyses. Next, a risk score formula was established for evaluating patient outcome in GC and validated by survival and ROC curves. In addition, Kaplan-Meier curves were generated to assess the associations of the clinicopathological data with prognosis. And a cohort from the Gene Expression Omnibus (GEO) database was used for validation. RESULTS: Six EMT-related genes, including CDH6, COL5A2, ITGAV, MATN3, PLOD2, and POSTN, were identified. Based on the risk model, GC patients were assigned to the high- and low-risk groups. The results revealed that the model had good performance in predicting patient prognosis in GC. CONCLUSIONS: We constructed a prognosis risk model for GC. Then, we verified the performance of the model, which may help doctors predict patient prognosis.
BACKGROUND:Gastric cancer (GC) represents a major malignancy and is the third deathliest cancer globally. Several lines of evidence indicate that the epithelial-mesenchymal transition (EMT) has a critical function in the development of gastric cancer. Although plentiful molecular biomarkers have been identified, a precise risk model is still necessary to help doctors determine patient prognosis in GC. METHODS: Gene expression data and clinical information for GC were acquired from The Cancer Genome Atlas (TCGA) database and 200 EMT-related genes (ERGs) from the Molecular Signatures Database (MSigDB). Then, ERGs correlated with patient prognosis in GC were assessed by univariable and multivariable Cox regression analyses. Next, a risk score formula was established for evaluating patient outcome in GC and validated by survival and ROC curves. In addition, Kaplan-Meier curves were generated to assess the associations of the clinicopathological data with prognosis. And a cohort from the Gene Expression Omnibus (GEO) database was used for validation. RESULTS: Six EMT-related genes, including CDH6, COL5A2, ITGAV, MATN3, PLOD2, and POSTN, were identified. Based on the risk model, GC patients were assigned to the high- and low-risk groups. The results revealed that the model had good performance in predicting patient prognosis in GC. CONCLUSIONS: We constructed a prognosis risk model for GC. Then, we verified the performance of the model, which may help doctors predict patient prognosis.
Authors: Taiwen Li; Jingyu Fan; Binbin Wang; Nicole Traugh; Qianming Chen; Jun S Liu; Bo Li; X Shirley Liu Journal: Cancer Res Date: 2017-11-01 Impact factor: 12.701
Authors: Robert Sitarz; Małgorzata Skierucha; Jerzy Mielko; G Johan A Offerhaus; Ryszard Maciejewski; Wojciech P Polkowski Journal: Cancer Manag Res Date: 2018-02-07 Impact factor: 3.989
Authors: Xu Zhaojun; Chen Xiaobin; An Juan; Yuan Jiaqi; Jiang Shuyun; Liu Tao; Cai Baojia; Wang Cheng; Ma Xiaoming Journal: World J Surg Oncol Date: 2022-01-03 Impact factor: 2.754